Key Ideas

The treatment landscape for relapsed and refractory diffuse large B-cell lymphoma has shifted from a single question, transplant eligible or not, to a broader one centered on CAR-T eligibility, which now applies to nearly every patient. Bispecific antibody combinations are rapidly filling the gap for patients who cannot reach CAR-T, and frontline therapy itself is poised to become considerably more crowded within the next year.

From "Transplant Eligible" to "CAR-T Eligible"

For decades, the central question facing a relapsed diffuse large B-cell lymphoma patient was whether they could tolerate high-dose chemotherapy and autologous stem cell transplant. Updated NCCN guidance has reframed that question entirely: the second-line treatment algorithm now sorts patients by CAR-T candidacy rather than transplant eligibility, and those categories are not the same. CAR-T eligibility criteria are broad. Patients well into their eighties have received CAR-T therapy, and there is effectively no upper age cutoff; the population that is truly ineligible is limited to those who are actively dying or experiencing active end-organ failure. Every patient with relapsed lymphoma deserves referral to a cellular therapy specialist for a formal fitness evaluation before anyone, including their own treating oncologist, concludes they are not a candidate.

That broad eligibility has not translated into broad access. Despite theoretical eligibility, estimates suggest fewer than 30% of patients who should be considered for CAR-T actually reach a CAR-T center and undergo the potentially curative therapy. Access barriers persist even in major metropolitan areas, driven by insurance structure, care coordination gaps, and disease biology that may not allow enough time for referral and workup, not simply geographic distance from a treatment center.

CAR-T's Established Track Record in Second Line

Two cellular therapy products, axicabtagene ciloleucel and lisocabtagene maraleucel, are approved for second-line use in patients who relapse within 12 months of frontline chemoimmunotherapy or who are primary refractory, based on the pivotal ZUMA-7 and TRANSFORM trials respectively. Both trials randomized patients to CAR-T versus standard-of-care bridging followed by autologous transplant, and both showed clear superiority for the cellular therapy arm on progression-free and event-free survival. Long-term follow-up continues to support durability: four-year progression-free survival with lisocabtagene maraleucel reached 52.2%, a figure consistent with curing roughly half of this relapsed population, a result that would have been unimaginable in this setting a decade ago.

Patients who relapse after 12 months, so-called late relapsers, remain more chemosensitive as a group, and autologous transplant retains a role for appropriately selected patients in that category, an important distinction from the early-relapse and primary refractory population where CAR-T has become the clear standard.

Bispecific Antibodies: Filling the Gap When CAR-T Isn't Happening

For patients who cannot reach CAR-T, whether due to disease pace, comorbidities, or access barriers, bispecific antibody-based regimens have become the most exciting development in this space. Currently, bispecific antibody monotherapy is approved in the United States only as third-line treatment; second-line bispecific combinations remain unapproved domestically, even where strong trial data exists.

The STARGLO trial, combining glofitamab with gemcitabine and oxaliplatin (GemOx) against rituximab-GemOx in transplant-ineligible relapsed or refractory disease, produced a strong overall survival signal internationally, with three-year follow-up showing median overall survival of 25.5 months versus 12.5 months and complete response rates of 58.5% versus 25.3% favoring the glofitamab combination. Glofitamab itself remains approved as monotherapy for patients with two or more prior lines of therapy.

The SUNMO trial tells a more promising domestic story. Combining mosunetuzumab with polatuzumab vedotin against rituximab-GemOx in transplant-ineligible relapsed or refractory large B-cell lymphoma, SUNMO nearly tripled median progression-free survival (11.5 versus 3.8 months) and more than doubled complete response rates (51.4% versus 24.3%), all delivered as a fixed-duration, fully chemotherapy-free outpatient regimen. This combination has become a preferred option in practice for the transplant-ineligible population, offering efficacy without the infrastructure demands of cellular therapy.

Third Line and Beyond: A Growing but Uneven Toolbox

Once patients reach third-line treatment, the available options expand considerably, though FDA approval and NCCN endorsement do not always align. Tafasitamab combined with lenalidomide has produced long-standing durable responses among responders and remains a favored non-chemotherapy option, particularly for older patients who cannot tolerate additional cytotoxic therapy. Polatuzumab vedotin combined with bendamustine-rituximab, loncastuximab tesirine, epcoritamab, and glofitamab monotherapy round out an expanding third-line treatment, and brentuximab vedotin combined with lenalidomide has recently gained third-line approval as well, adding yet another tool, even as clinical experience with identifying the right patient for that specific combination is still developing.

Bridging Therapy: A Balancing Act Before CAR-T

Choosing bridging therapy while a patient awaits CAR-T manufacturing requires coordination with the treating cellular therapy team. Radiotherapy for bulky or oligoprogressive disease is often a preferred bridging strategy given its targeted, low-toxicity profile. Using bispecific antibodies as bridging therapy before apheresis raises legitimate concern about T-cell exhaustion, and using CD19-targeted therapy before collection carries similar theoretical risk, even though emerging data suggest that risk may be smaller than initially feared. As a general practice, any CD19-directed bridging strategy should be discussed directly with the CAR-T provider beforehand rather than initiated independently. Once apheresis has occurred, this concern largely resolves. Bendamustine and other disease-controlling agents can be used more freely post-apheresis to keep disease in check while a patient's own manufactured product is prepared.

What's Coming to Frontline Therapy

Frontline treatment for diffuse large B-cell lymphoma has remained largely unchanged for over two decades, built around R-CHOP, with polatuzumab vedotin plus R-CHP (the POLARIX regimen) representing the first meaningful advance since rituximab itself was added to CHOP. That is about to change substantially. The frontMIND trial, adding tafasitamab and lenalidomide to R-CHOP in newly diagnosed high-intermediate- and high-risk disease, met its primary endpoint with a 25% reduction in risk of progression or death and improved three-year progression-free survival (67.3% versus 60.7%) regardless of molecular subtype, positioning this triplet as a likely new frontline standard once regulatory review concludes. Separately, pivotal readouts are anticipated for bispecific antibody combinations added directly to the CHOP backbone in the frontline setting. By the end of 2027, frontline treatment for this disease is likely to look considerably more crowded, and considerably more individualized, than it does today, which is unambiguously good news for patients even as it demands more nuanced decision-making from their oncologists.

For Patients

Treatment options for diffuse large B-cell lymphoma that relapses or does not respond to initial chemotherapy have expanded dramatically. CAR-T cell therapy, which reprograms a patient's own immune cells to attack the lymphoma, has become the preferred second-line treatment for patients who relapse within a year of their first treatment or whose lymphoma never fully responded. Eligibility for CAR-T is broader than many patients realize. Nearly everyone, including patients in their eighties, should be evaluated by a specialist rather than assumed to be ineligible based on age alone.

For patients who cannot access CAR-T, whether due to how quickly their disease is progressing, other health conditions, or practical barriers to reaching a specialized treatment center, newer antibody-based treatments called bispecific antibodies are proving to be strong alternatives. These treatments engage a patient's own immune cells to attack the cancer without requiring cell collection and manufacturing, and some combinations are now delivered entirely as outpatient care.

Patients whose lymphoma has relapsed should ask specifically whether they have been evaluated for CAR-T therapy by a cellular therapy specialist, since eligibility is broader than many people expect, and access gaps rather than medical unsuitability are often what keep eligible patients from receiving this potentially curative treatment. Frontline treatment options are also expected to change substantially over the next one to two years, so newly diagnosed patients, particularly those with higher-risk disease features, should ask their care team about emerging combination therapies and relevant clinical trials.

Key Takeaways

  • Updated NCCN guidance now sorts relapsed diffuse large B-cell lymphoma patients by CAR-T candidacy rather than transplant eligibility; CAR-T eligibility criteria are broad, with essentially no upper age limit, yet fewer than 30% of eligible patients currently reach a CAR-T center.
  • Axicabtagene ciloleucel and lisocabtagene maraleucel are both approved second-line CAR-T products for early relapse or primary refractory disease, with four-year progression-free survival around 52% with lisocabtagene maraleucel in long-term follow-up.
  • Bispecific antibody combinations, particularly mosunetuzumab plus polatuzumab vedotin (SUNMO), nearly tripled progression-free survival compared with chemoimmunotherapy in transplant-ineligible relapsed disease and are increasingly favored when CAR-T is not accessible.
  • The glofitamab-GemOx combination showed strong overall survival benefit in the STARGLO trial internationally; glofitamab monotherapy remains approved in the third-line setting.
  • Frontline therapy is expected to change substantially over the next one to two years, with tafasitamab plus lenalidomide added to R-CHOP (frontMIND) showing a 25% reduction in progression or death risk in high-risk disease, and bispecific-CHOP combination trial readouts anticipated soon.

References

  1. Locke FL, Ahmed S, Neelapu SS, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma (ZUMA-7). New England Journal of Medicine. 2022.
  2. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care as second-line treatment for large B-cell lymphoma (TRANSFORM). Lancet. 2022.
  3. Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024.
  4. Budde LE, Zhang H, Kim WS, et al. Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. Journal of Clinical Oncology. 2025.
  5. Lenz G, Vitolo U, Burke J, et al. Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026.
  6. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma (POLARIX). New England Journal of Medicine. 2022.